Advertisement

August 19, 2019

Boston Scientific Closes Acquisition of BTG

August 19, 2019—Boston Scientific Corporation announced the completion of its acquisition of BTG plc pursuant to the agreement first announced in late 2018. Upon the effectiveness of the scheme of arrangement, BTG became a wholly owned subsidiary of Boston Scientific. Shares of BTG are no longer traded on the London Stock Exchange.

According to the announcement, BTG develops and commercializes products used in minimally invasive procedures targeting cancer and vascular diseases, as well as specialty pharmaceuticals. BTG's three key businesses include the interventional medicine portfolio that encompasses interventional oncology therapeutic technologies for patients with liver and kidney cancers; the vascular portfolio for treatment of deep vein thrombosis, pulmonary embolism, deep venous obstruction, and superficial venous disease; and the specialty pharmaceutical business comprised of acute care antidotes to treat overexposure to certain medications and toxins, as well as a licensing business that receives royalties related to BTG intellectual property and product license agreements.

Boston Scientific expects to complete the previously announced sale of its global embolic microspheres portfolio to Varian Medical Systems, Inc. The portfolio is comprised of the Embozene, Embozene Tandem, and Oncozene brands. This transaction is connected to obtaining the antitrust clearances required to complete the BTG transaction. In addition, Boston Scientific is exploring the divestiture of the royalty stream associated with BTG's Zytiga licensing arrangements and anticipates closing this divestiture by the end of 2019.

Advertisement


August 19, 2019

Five-Year Data Published for ENGAGE Global Registry of Medtronic's Endurant EVAR Device

August 19, 2019

Vascular Therapies Completes Enrollment in the Phase 3 ACCESS Trial